Is Lantheus Holdings, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Lantheus Holdings, Inc. has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 15, an EV to EBITDA ratio of 10.33, and a robust ROCE of 56.47%. In comparison, QIAGEN NV has a significantly higher P/E ratio of 24.20, while Bio-Rad Laboratories, Inc. shows a P/E of 16.20, highlighting Lantheus's relative attractiveness in the market.
Despite recent struggles, with a year-to-date return of -37.85% compared to the S&P 500's 13.30%, Lantheus has demonstrated strong long-term performance, with a 5-year return of 316.48% versus the S&P 500's 91.29%. This suggests that while the stock has faced challenges recently, its underlying value and potential for recovery remain compelling.